"In 25 years of experience in treating congestive heart failure, we have consistently seen the best response when CoQ10 is begun early in the course of the disease," said Dr. Langsjoen, who conducted the research in Tyler, Texas.
"The improvement in ejection fraction levels in these seven patients with end-stage congestive heart failure was associated with overall clinical improvement. It is likely that ubiquinol would show even more clinical benefit in early congestive heart failure. Future controlled trials of Kaneka QH(TM) in congestive heart failure are anxiously awaited."
About Kaneka QH(TM) (ubiquinol)
Both ubiquinone and ubiquinol are essential to generating cellular energy and sustaining life; however, the reduced form, ubiquinol, is responsible for the powerful antioxidant benefits associated with CoQ10. More than 90 percent of the CoQ10 found in a healthy person's plasma is in its reduced ubiquinol form.
For the past 40 years, only ubiquinone was available as a supplement. KanekaQH(TM), the world's only supplemental ubiquinol, has only been available since late 2006. The ingredient, manufactured exclusively by Kaneka, is currently available in more than 30 consumer supplements.
"Cardiovascular patients, those fighting age-related diseases and even healthy people over the age of 40 have a critical need to optimize the EF and plasma CoQ10 levels within their bodies," explained Dr. Robert Barry of Kaneka Nutrients, L.P. "Because it's so much better absorbed by the body, KanekaQH(TM) can raise CoQ10 levels more effectively and, as we're seeing from Dr. Langsjoen's s
|SOURCE Kaneka Nutrients L.P.|
Copyright©2009 PR Newswire.
All rights reserved